Deucravacitinib CAS# 1609392-27-9

Deucravacitinib (BMS-986165) is a selective, oral allosteric inhibitor of tyrosine kinase 2 (TYK2). Unlike JAK1/2/3 inhibitors, it binds the regulatory pseudokinase (JH2) domain of TYK2 with high affinity (IC50 ~1 nM), preventing activation without blocking the ATP-binding catalytic site. In preclinical studies, deucravacitinib potently inhibited IL-12, IL-23, and type I interferon signaling pathways in human immune cells, reducing STAT phosphorylation and downstream cytokine production (IC50 values in the low nanomolar range). In murine models of psoriasis and autoimmune inflammation, it significantly reduced disease severity. Pharmacokinetic studies confirmed good oral exposure, supporting its advancement into clinical trials for immune-mediated diseases.